drugset
drugset / Trial / NCT00650156

Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

NCT00650156 ↗

Phase 1 Completed 24 enrolled AbbVie
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Pharmacokinetic and Safety Study with Adalimumab in Chinese Subjects with Mild Rheumatoid Arthritis

Timeline

Start
2007-06
Primary completion
2007-10
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Adalimumab Monoclonal antibody 80 mg Subcutaneous

Indications

rheumatoid arthritis